APGE
Apogee Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APGE
Apogee Therapeutics, Inc.
A biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
Biological Technology
06/09/2023
07/14/2023
NASDAQ Stock Exchange
196
12-31
Common stock
221 Crescent St., Building 17, Suite 102b, Waltham, MA 02453
--
Apogee Therapeutics, Inc.was incorporated on June 9, 2023 as a Delaware corporation. In connection with this offering, as a holding company, it will wholly own Apogee Therapeutics, LLC and indirectly own its subsidiaries. The Company is a biotechnology company developing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunological indications for which unmet needs exist. The company's antibody program aims to overcome the limitations of existing therapies, target mature mechanisms of action, and combine advanced antibody engineering to optimize half-life.
Company Financials
EPS
APGE has released its 2025 Q3 earnings. EPS was reported at -1.11, versus the expected -1.15, beating expectations. The chart below visualizes how APGE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
